In Brief: Sanofi Skelid
Executive Summary
Sanofi Skelid: Phase III clinical trials of tiludronate in the treatment of osteoporosis are investigating both 200 mg/day and 50 mg/day doses. Dosage is cyclical, with 7 days of drug followed by 21 days of calcium supplementation. Skelid was approved for treatment of Paget's disease March 7 ("The Pink Sheet" March 17, p. 11)...